AHGAkso Health Group
Akso Health Group (AHG) offers professional services in the information technology sector, focusing on healthcare IT solutions. The company’s next catalyst is Nov 5, 2026 — Q4 Earnings Release, which will test its ability to scale revenue growth while managing its persistent negative net margin.
- Revenue surged 259.6% YoY to $6.31M, but net income remains -$18.67M, with a TTM net margin of -295.9%.
- Free cash flow is -$12.79M, and diluted EPS is 0.01, reflecting a cash-burn business model.
- Shareholders’ equity stands at $180.93M, but the company has yet to turn a profit.
The schedule
- Thu5Nov
The earnings report will test the company's ability to meet revenue and EPS guidance, with a focus on operational efficiency and cost management. This differs from the last print where the company underperformed due to supply chain disruptions.
- Thu3Dec
The conference call will provide insight into management's confidence in the guidance and any strategic shifts. This will test the company's communication and transparency, which were lacking in the last call.
- Thu7Jan
The Q1 earnings will test the company's ability to sustain growth and meet expectations after the Q4 report. This will be a key moment to assess the impact of any strategic initiatives or cost-cutting measures.
- Wed3Feb
The Q2 2027 earnings release will test the company's ability to deliver on its growth strategy and meet revenue targets, particularly in light of recent market volatility and macroeconomic uncertainty.
- Thu4Feb
The conference call will provide further insight into the Q1 performance and management's outlook. This will test the company's ability to communicate progress and address any concerns raised by investors.
- Wed5May
The Q3 2027 earnings release will test the company's ability to sustain momentum from the previous quarter and adapt to evolving market conditions, particularly in the health care sector.
- Wed4Aug
The Q4 2027 earnings release will test the company's ability to close the year on a strong note, with a focus on year-over-year growth and the effectiveness of its long-term strategic plans.
- Wed3Nov
The Q1 2028 earnings release will test the company's ability to maintain performance momentum and adapt to new market dynamics, particularly in the health care sector.
Past
- Wed23Sep
Actual outcome: Bull · $1.37 at outcome
AHG reported stronger-than-expected earnings and raised revenue guidance, signaling improved operational performance and future growth prospects. The results exceeded analyst expectations, leading to a significant upward re-rating of the stock. The move reflects confidence in the company's ability to sustain momentum. [Market retrospective · Medium-Term (11–30 days)] Missed anticipation: +71.3% from 2026-09-23 to 2026-11-04 (~2.2σ vs typical 30d vol). Target date 2026-10-14 reached; move through 2026-11-04 observed. Confidence 95%.
AHG reported stronger-than-expected earnings and raised revenue guidance, signaling improved operational performance and future growth prospects. The results exceeded analyst expectations, leading to a significant upward re-rating of the stock. The move reflects confidence in the company's ability to sustain momentum. [Market retrospective · Medium-Term (11–30 days)] Missed anticipation: +71.3% from 2026-09-23 to 2026-11-04 (~2.2σ vs typical 30d vol). Target date 2026-10-14 reached; move through 2026-11-04 observed. Confidence 95%.